Alkermes kept at buy at Merrill

Alkermes Inc. was maintained at buy and its 12-month price objective kept unchanged at $19.00 by Merrill Lynch analyst Hari Sambasivam on news of the company's deal with Cephalon. Merrill also revised its fiscal 2006 and 2007 loss-per-share estimates to $0.31 and $0.08 from $0.71 and $0.18, respectively to reflect Alkermes' partnership with Vivitrex. Alkermes shares closed Thursday down $0.07, or 0.45%, at $15.40 on volume of 551,134 shares compared to a three-month trailing average of 1,029,020 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.